

From: [CRPM \(Cory Potomis\)](#)
To: [AGO - High Cost Prescription Drugs](#)
Subject: New Prescription Drug 3 Day Notice from Novo Nordisk Inc. - Rybelsus Oral Tablet
Date: Thursday, October 24, 2019 11:59:16 AM
Attachments: [image002.png](#)
[image004.png](#)
[image006.png](#)
[image008.png](#)

To the Vermont Attorney General Office,

I am writing today to give 3 day notice regarding the introduction of a new prescription drug to market from Novo Nordisk Inc.:

NDC	Drug Product Description	Introduced to Market Date	WAC at Intro to Market
00169430313	Rybelsus Oral Tablet 3 MG	10/22/2019	\$772.43
00169430713	Rybelsus Oral Tablet 7 MG	10/22/2019	\$772.43
00169431413	Rybelsus Oral Tablet 14 MG	10/22/2019	\$772.43

Thank you,
Cory Potomis

Cory Potomis
Associate Director, Ethics & Compliance Operations

Novo Nordisk Inc.
800 Scudders Mill Road
Plainsboro, NJ 08536
+1 609-987-5800 (switchboard)

+16097865321 (direct)
+16092123782 (mobile)
www.novonordisk-us.com



This e-mail (including any attachments) is intended for the addressee(s) stated above only and may contain confidential information protected by law. You are hereby notified that any unauthorized reading, disclosure, copying or distribution of this e-mail or use of information contained herein is strictly prohibited and may violate rights to proprietary information. If you are not an intended recipient, please return this e-mail to the sender and delete it immediately hereafter. Thank you.